GlaxoSmithKline PLC
ISIN: GB00BN7SWP63 | Ticker: GSK | LEI: 5493000HZTVUYLO1D793
Country: United Kingdom
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
2000
Served areaWorldwide
Headcount69,400
HeadquartersC8 Gsk House, 980 Great West Road, TW8 9GS Brentford – United Kingdom
| Line item in (gbp) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | 80,431,000,000.00 | 79,103,000,000.00 | 60,146,000,000.00 |
| Noncurrent Assets | N/A | N/A | 60,184,000,000.00 | 60,429,000,000.00 | 39,377,000,000.00 |
| Property Plant And Equipment | N/A | N/A | 10,176,000,000.00 | 9,932,000,000.00 | 8,933,000,000.00 |
| Goodwill | N/A | N/A | 10,597,000,000.00 | 10,552,000,000.00 | 7,046,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 29,824,000,000.00 | 30,079,000,000.00 | 14,318,000,000.00 |
| Investment Accounted For Using Equity Method | N/A | N/A | 364,000,000.00 | 88,000,000.00 | 74,000,000.00 |
| Deferred Tax Assets | N/A | N/A | 4,287,000,000.00 | 5,218,000,000.00 | 5,658,000,000.00 |
| Noncurrent Derivative Financial Assets | N/A | N/A | 5,000,000.00 | 18,000,000.00 | 0.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | N/A | N/A | 2,126,000,000.00 | 1,467,000,000.00 |
| Other Noncurrent Assets | N/A | N/A | 1,041,000,000.00 | 1,676,000,000.00 | 1,194,000,000.00 |
| Current Assets | N/A | N/A | 20,247,000,000.00 | 18,674,000,000.00 | 20,769,000,000.00 |
| Inventories | N/A | N/A | 5,996,000,000.00 | 5,783,000,000.00 | 5,146,000,000.00 |
| Trade And Other Current Receivables | N/A | N/A | 6,952,000,000.00 | 7,860,000,000.00 | 7,053,000,000.00 |
| Other Current Financial Assets | N/A | N/A | 78,000,000.00 | 61,000,000.00 | 67,000,000.00 |
| Current Financial Assets At Fair Value Through Profit Or Loss Classified As Held For Trading | N/A | N/A | N/A | 0.00 | 4,087,000,000.00 |
| Cash and cash equivalents | N/A | 4,707,000,000.00 | 6,292,000,000.00 | 4,274,000,000.00 | 3,723,000,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | 106,000,000.00 | 22,000,000.00 | 98,000,000.00 |
| Current Derivative Financial Assets | N/A | N/A | 152,000,000.00 | 188,000,000.00 | 190,000,000.00 |
| Equity | 3,672,000,000.00 | 18,357,000,000.00 | 20,808,000,000.00 | 21,342,000,000.00 | 10,096,000,000.00 |
| Issued Capital | N/A | N/A | 1,346,000,000.00 | 1,347,000,000.00 | 1,347,000,000.00 |
| Retained Earnings | N/A | N/A | 6,755,000,000.00 | 7,944,000,000.00 | 4,363,000,000.00 |
| Share Premium | N/A | N/A | 3,281,000,000.00 | 3,301,000,000.00 | 3,440,000,000.00 |
| Other Reserves | N/A | N/A | 3,205,000,000.00 | 2,463,000,000.00 | 1,448,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 14,587,000,000.00 | 15,055,000,000.00 | 10,598,000,000.00 |
| Noncontrolling Interests | N/A | N/A | 6,221,000,000.00 | 6,287,000,000.00 | -502,000,000.00 |
| Liabilities | N/A | N/A | 59,623,000,000.00 | 57,761,000,000.00 | 50,050,000,000.00 |
| Noncurrent Liabilities | N/A | N/A | 37,475,000,000.00 | 34,091,000,000.00 | 27,240,000,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | N/A | 3,650,000,000.00 | 3,113,000,000.00 | 2,579,000,000.00 |
| Other Longterm Provisions | N/A | N/A | 707,000,000.00 | 630,000,000.00 | 532,000,000.00 |
| Deferred Tax Liabilities | N/A | N/A | 3,600,000,000.00 | 3,556,000,000.00 | 289,000,000.00 |
| Current Tax Liabilities Noncurrent | N/A | N/A | 176,000,000.00 | 180,000,000.00 | 127,000,000.00 |
| Other Noncurrent Financial Liabilities | N/A | N/A | 5,104,000,000.00 | 5,118,000,000.00 | 5,779,000,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | N/A | 10,000,000.00 | 1,000,000.00 | 0.00 |
| Other Noncurrent Liabilities | N/A | N/A | 803,000,000.00 | 921,000,000.00 | 899,000,000.00 |
| Longterm Borrowings | N/A | N/A | 23,425,000,000.00 | 20,572,000,000.00 | 17,035,000,000.00 |
| Current Liabilities | N/A | N/A | 22,148,000,000.00 | 23,670,000,000.00 | 22,810,000,000.00 |
| Other Shortterm Provisions | N/A | N/A | 1,052,000,000.00 | 841,000,000.00 | 652,000,000.00 |
| Trade And Other Current Payables | N/A | N/A | 15,840,000,000.00 | 17,554,000,000.00 | 16,263,000,000.00 |
| Other Current Financial Liabilities | N/A | N/A | 765,000,000.00 | 958,000,000.00 | 1,289,000,000.00 |
| Current Derivative Financial Liabilities | N/A | N/A | 221,000,000.00 | 227,000,000.00 | 183,000,000.00 |
| Line item in (gbp) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 33,754,000,000.00 | 24,354,000,000.00 | 24,696,000,000.00 | 29,324,000,000.00 |
| Revenue From Royalties | 351,000,000.00 | 321,000,000.00 | 417,000,000.00 | 758,000,000.00 |
| Profit Loss From Operating Activities | 6,961,000,000.00 | 5,979,000,000.00 | 4,357,000,000.00 | 6,433,000,000.00 |
| Finance Income | 98,000,000.00 | 32,000,000.00 | 14,000,000.00 | 76,000,000.00 |
| Finance Costs | 912,000,000.00 | 874,000,000.00 | 769,000,000.00 | 879,000,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 74,000,000.00 | 33,000,000.00 | 33,000,000.00 | -2,000,000.00 |
| Profit Loss Before Tax | 6,221,000,000.00 | 5,170,000,000.00 | 3,599,000,000.00 | 5,628,000,000.00 |
| Income Tax Expense Continuing Operations | 953,000,000.00 | 67,000,000.00 | 83,000,000.00 | 707,000,000.00 |
| Profit Loss From Continuing Operations | N/A | 5,103,000,000.00 | 3,516,000,000.00 | 4,921,000,000.00 |
| Profit Loss From Discontinued Operations | N/A | 1,285,000,000.00 | 1,580,000,000.00 | 10,700,000,000.00 |
| Profit (loss) | 5,268,000,000.00 | 6,388,000,000.00 | 5,096,000,000.00 | 15,621,000,000.00 |
| Profit Loss Attributable To Owners Of Parent | 4,645,000,000.00 | 5,749,000,000.00 | 4,385,000,000.00 | 14,956,000,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 623,000,000.00 | 639,000,000.00 | 711,000,000.00 | 665,000,000.00 |
| Line item in (gbp) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | 5,268,000,000.00 | 6,388,000,000.00 | 5,096,000,000.00 | 15,621,000,000.00 |
| Adjustments For Reconcile Profit Loss | 4,264,000,000.00 | 2,571,000,000.00 | 3,733,000,000.00 | 3,023,000,000.00 |
| Adjustments For Reconcile Profit Loss | 4,264,000,000.00 | 2,571,000,000.00 | 3,733,000,000.00 | 3,023,000,000.00 |
| Cash Flows From Used In Operations | 9,532,000,000.00 | 7,674,000,000.00 | 7,249,000,000.00 | 7,944,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 1,512,000,000.00 | 1,655,000,000.00 | 1,291,000,000.00 | N/A |
| Cash Flows From Used In Operating Activities | 8,020,000,000.00 | 8,441,000,000.00 | 7,952,000,000.00 | 7,403,000,000.00 |
| Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | 69,000,000.00 | 3,269,000,000.00 | 202,000,000.00 | 238,000,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | 258,000,000.00 | 411,000,000.00 | 162,000,000.00 | 143,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 95,000,000.00 | 49,000,000.00 | 132,000,000.00 | 146,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 1,265,000,000.00 | 989,000,000.00 | 950,000,000.00 | 1,143,000,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 404,000,000.00 | 343,000,000.00 | 641,000,000.00 | 196,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 898,000,000.00 | 956,000,000.00 | 1,704,000,000.00 | 1,115,000,000.00 |
| Dividends Received Classified As Investing Activities | 7,000,000.00 | 31,000,000.00 | 9,000,000.00 | 6,000,000.00 |
| Interest Received Classified As Investing Activities | 82,000,000.00 | 27,000,000.00 | 14,000,000.00 | 64,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | -113,000,000.00 | -120,000,000.00 | -114,000,000.00 | -79,000,000.00 |
| Cash Flows From Used In Investing Activities | -5,354,000,000.00 | 2,161,000,000.00 | -1,777,000,000.00 | -8,772,000,000.00 |
| Payments From Changes In Ownership Interests In Subsidiaries | 7,000,000.00 | 0.00 | 0.00 | N/A |
| Proceeds From Issuing Shares | 51,000,000.00 | 29,000,000.00 | 21,000,000.00 | 25,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 214,000,000.00 | 182,000,000.00 | 181,000,000.00 | 202,000,000.00 |
| Interest Paid Classified As Financing Activities | 895,000,000.00 | 851,000,000.00 | 772,000,000.00 | 848,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | -187,000,000.00 | -89,000,000.00 | 40,000,000.00 | 376,000,000.00 |
| Cash Flows From Used In Financing Activities | -1,840,000,000.00 | -10,132,000,000.00 | -7,589,000,000.00 | 823,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 826,000,000.00 | 470,000,000.00 | -1,414,000,000.00 | -546,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -82,000,000.00 | -39,000,000.00 | -29,000,000.00 | 152,000,000.00 |
| Cash and cash equivalents | 4,707,000,000.00 | 6,292,000,000.00 | 4,274,000,000.00 | 3,723,000,000.00 |
Please note that some sums might not add up.
GB00BN7SWP63
LEI5493000HZTVUYLO1D793
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 100
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.